30 / 39
Page 88
Notes:
allied
academies
February 28-March 01, 2019 | Paris, France
Palliative Care, Obstetrics and Gynecology
Stroke and Clinical Trials
International Conference on
Joint Event on
International Conference on
&
Journal of Research and Reports in Gynecology and Obstetrics | Volume: 3
Completeresponseof stageIVpancreaticcancercombining low-dosecheckpoint inhibitorswithinterleukin-2
(IL-2) and fever range hyperthermia
Ralf Kleef, Robert Nagy, Arthur Bohdjalian, Viktor Bacher, Alina Wychera, Susanna Kekic, Dwight McKee, Hans Bojar
and
Ralph Moss
Immunology & Integrative Oncology, Austria
Advanced stage inoperable pancreatic cancer has a poor
prognosis and patients rarely enjoy durable complete response
to treatment; progression free survival often is limited.
Materials and methods:
The patient was a 45-year-old male
newly diagnosed 05/2017 with adenocarcinoma of the
pancreas with histological confirmation of primary invasive
ductal adenocarcinoma of the pancreas with disseminated
liver metastasis (>20 single lesions up to 2cm) and a single
large peritoneal deposit (2.7×2.0×3.9 cm) close to the caecum.
There was small volume malignant ascites. Histology revealed
adenocarcinoma stage UICC IV T2 N2 M1 (hepar, peritoneum)
with disseminated para-aortal and celiac lymph nodemetastasis.
The patient underwent one-time neoadjuvant CHT with
Gemcitabine–Abraxaneprior.Therapyconsistedofadministration
of combination protocol with Checkpoint inhibitor therapy (anti
PD-1/CTLA-4) in combination with endogenous and exogenous
hyperthermia as described previously.
Results:
First restaging 11/2017 three month following initiation
of therapy with CT of abdomen and pelvis demonstrated major
partial remission with decrease of the size of disseminated liver
metastasis and no measurable primary pancreatic tumour,
vanishing of the previously described lymphadenopathy. At that
time the patient had started gaining weight again and was free
of any cancer-related symptoms. Second restaging 05/2018 nine
months following initiation of therapy with CT of the abdomen
and indicated complete remission. Follow-up time now is 1½
years. Patient is healthy and free of any symptoms.
Conclusion:
This is one of several cases of advanced stage cancer
patients having a complete response to primary immunotherapy
treatment. Clearly, this combination immune therapy warrants
further clinical studies.
e:
ralf.kleef@dr-kleef.atRes Rep Gynaecol Obstet, Volume 3
DOI: 10.4066/2591-7366-C1-003